超越奥希替尼:晚期EGFR突变NSCLC第三代EGFR酪氨酸激酶抑制剂的研发进展
单药奥希替尼是晚期EGFR突变NSCLC一线标准治疗,且直至2020年3月阿美替尼(HS-10296)在中国获批治疗EGFR T790M阳性NSCLC前,一直是唯一上市的三代EGFR TKI。本综述基于1/2期试验中期结果介绍了多种晚期临床开发中的三代EGFR TKI(如阿美替尼、拉泽替尼等),并汇总了已报告药物的临床试验结果及联合试验设计(FLAURA2、MARIPOSA、ACROSS1/2)。
要点
- 奥希替尼是晚期EGFR突变NSCLC一线标准治疗,阿美替尼于2020年3月在中国获批用于EGFR T790M阳性NSCLC。
- 多种三代EGFR TKI处于晚期临床开发,基于1/2期试验中期结果进行了介绍。
- FLAURA2、MARIPOSA、ACROSS1/2等联合试验若阳性可能确立下一个标准治疗。
核心结论
- 单药奥希替尼是晚期EGFR突变NSCLC一线标准治疗,阿美替尼是首个在中国获批的三代EGFR TKI。
- 多种三代EGFR TKI正在晚期临床开发中,联合试验可能改变未来标准治疗。
研究设计与样本
- 本综述基于1期和2期试验的中期结果,介绍了多种三代EGFR TKI的临床开发情况。
- 综述还纳入了公开可得的3期试验设计及化学结构,并检索临床试验注册网站列出了其他在研三代EGFR TKI。
主要发现
- 阿美替尼(HS-10296)基于1/2期试验的2期扩展研究结果,于2020年3月在中国获批治疗晚期EGFR T790M阳性NSCLC。
- 综述介绍了阿美替尼、拉泽替尼、alflutinib、rezivertinib、ASK120069、SH-1028、D-0316和abivertinib等三代EGFR TKI的1/2期试验中期结果。
- 综述还总结了既往报告的三代EGFR TKI(rociletinib、olmutinib、nazartinib、mavelertinib)的临床试验结果,包括rociletinib和naquotinib的3期结果。
临床怎么用
- 奥希替尼仍是晚期EGFR突变NSCLC一线标准治疗,阿美替尼可作为EGFR T790M阳性NSCLC的治疗选择。
- 关注FLAURA2、MARIPOSA、ACROSS1/2等联合试验结果,可能影响未来治疗格局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Single-agent osimertinib is the standard of care for the first-line treatment of advancedEGFR+ NSCLC and remained the only marketed third-generation EGFR tyrosine kinase inhibitor (TKI) until March 2020 when almonertinib (HS-10296) was approved in the People's Republic of China for the treatment of advanced EGFR T790M+ NSCLC based on a phase 2 expansion study of a phase 1/2 trial. In this review, we profiled many of the third-generation EGFR TKIs in late-stage clinical development (e.g., almonertinib, lazertinib, alflutinib1, rezivertinib, ASK120069, SH-1028, D-0316, and abivertinib) based on their interim results from phase 1 and phase 2 trials, and included the designs of the phase 3 trials and their chemical structures when publicly available. We also listed other third-generation EGFR TKIs in pipeline development based on the search of clinical trial registration websites. In addition, we summarized the results of clinical trials that previously reported third-generation EGFR TKIs (rociletinib, olmutinib, nazartinib, mavelertinib), including phase 3 results of rociletinib and naquotinib. We further profiled combination clinical trial design of the third-generation EGFR TKIs including FLAURA2 (NCT04035486), MARIPOSA (NCT04487080), ACROSS1 (NCT04500704), and ACROSS2 (NCT04500717) that if positive can potentially usher in the next standard of care for advanced EGFR+ NSCLC.
引用
- Nagasaka M, Zhu VW, Lim SM, et al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2020. PMID: 33338652. doi:10.1016/j.jtho.2020.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。